Major Boost to the Global Esomeprazole Magnesium Market Analysis Forecast 2020-2025 | AstraZeneca, Radiant Pharmacuticals, Teva Pharmaceuticals, Mylan, Torrent Pharmaceutical, Camber

The growing demand for Esomeprazole Magnesium has provided a major boost to the Global Esomeprazole Magnesium Market as more people are shifting their preferences to this growing sector. The market is expected to keep rising at a high CAGR and reach values of high millions by the end of the forecast period of 2020 up to 2025.

Global Esomeprazole Magnesium Market overview:

Prescription esomeprazole is used to treat the symptoms of gastroesophageal reflux disease (GERD), a condition in which backward flow of acid from the stomach causes heartburn and possible injury of the esophagus (the tube between the throat and stomach) in adults and children 1 year of age and older. The Global Esomeprazole Magnesium Market is segmented on the basis of Product Type, Application, End Use Industry and Region. This report also covers all the regions and countries of the world, which shows a regional development status, including market size.

Available Exclusive Sample Copy of this Report @ https://www.businessindustryreports.com/sample-request/252926 .

On the Basis of Product Type segment, the Esomeprazole Magnesium Market is sub segmented into Capsules and Tablet. Based on End Use Industry segment, the Esomeprazole Magnesium Market is segmented as Antiulcer Agents and Acid Suppressants.

There are several manufacturers of Esomeprazole Magnesium in Europe and North America. In North America, the demand for Esomeprazole Magnesium is primarily driven by the Healthcare sector. Among the countries in Asia Pacific, the demand was substantially high in developing countries such as China and India.

Purchase this report online with 90 Pages, List of Tables & Figures and in-depth Table of Contents on “Esomeprazole Magnesium Market Report 2020” @ https://www.businessindustryreports.com/buy-now/252926/single .

Top Industry News:

Teva Announces New Analysis of Consistency in Migraine Days Over the Course of a Dosing Regimen for AJOVY (fremanezumab-vfrm) Injection Published in Headache on 07 October, 2020 -- Teva Pharmaceutical Industries Ltd. today announced results from a post hoc analysis of a long-term, open-label extension study assessing migraine days at the beginning and end of quarterly and monthly dosing intervals of AJOVY (fremanezumab-vfrm) injection. The results were published in the October issue of Headache: The Journal of Head and Face Pain.

“We are proud to share this analysis and demonstrate our continued commitment to advancing the understanding of treatment options for patients living with migraine,” said Denisa Hurtukova, MD, Vice President, Head of North America Medical Affairs, Teva. “This analysis helps us better understand patients’ experience with AJOVY, as well as the impact of quarterly and monthly dosing options.”

The post hoc analysis compared migraine days in the initial and final weeks of quarterly or monthly dosing regimens of AJOVY during up to 15 months of treatment. The analysis included 1,043 patients with chronic migraine (CM) (n=611) and episodic migraine (EM) (n=432) who were initially enrolled in the pivotal placebo controlled HALO CM and EM studies and then continued in the long-term, 12-month, multicenter, randomized, parallel group Phase 3 study with double blind dosing regimens. Patients received AJOVY either quarterly or monthly.

“Utilizing patients within each dosing group as their own control, we were able to analyze whether there was variability in migraine days over the course of a dosing regimen. For all time intervals analyzed, the frequency of migraine days was the same in the beginning and end of the dosing period,” said Joshua M. Cohen, MD, MPH, FAHS, Global Medical Therapeutic Area Lead for Migraine & Headache, Teva.

“This is an important analysis for the migraine community since clinical symptoms often return or worsen before the next dose of many preventive migraine medications is due,” said Andrew Blumenfeld, MD, Headache Center of Southern California, The Neurology Center, Carlsbad, CA. “Migraine can be a debilitating disease, so evaluating migraine days throughout a dosing regimen can be significant for healthcare providers when considering treatment options. Whenever the brain is exposed to a migraine attack, there is the possibility of increased sensitization with progressive worsening of the frequency of migraine. A key clinical goal is to limit the amount of time the brain is exposed to migraine to reduce this risk and the number of migraine days impacting a patient before their next dose.”

Grab Your Report at an Impressive Discount @ https://www.businessindustryreports.com/check-discount/252926 .

Major Key Players:

Some of the Esomeprazole Magnesium Market manufacturers involved in the market are AstraZeneca, Radiant Pharmacuticals, Teva Pharmaceuticals, Mylan, Torrent Pharmaceutical and Camber Pharmaceuticals in World, effective mergers are some of the strategies adopted by the Esomeprazole Magnesium Market manufacturers. New product launches and continuous technological innovations are the Esomeprazole Magnesium Market strategies adopted by the major players.

Table of Contents:

1 Esomeprazole Magnesium Product Definition
2 Global Esomeprazole Magnesium Market Manufacturer Share and Market Overview
2.1 Global Manufacturer Esomeprazole Magnesium Shipments
2.2 Global Manufacturer Esomeprazole Magnesium Business Revenue
2.3 Global Esomeprazole Magnesium Market Overview
3 Manufacturer Esomeprazole Magnesium Business Introduction
3.1 AstraZeneca Esomeprazole Magnesium Business Introduction
3.1.1 AstraZeneca Esomeprazole Magnesium Shipments, Price, Revenue and Gross profit 2014-2019
3.1.2 AstraZeneca Esomeprazole Magnesium Business Distribution by Region
3.1.3 AstraZeneca Interview Record
3.1.4 AstraZeneca Esomeprazole Magnesium Business Profile
3.1.5 AstraZeneca Esomeprazole Magnesium Product Specification
3.2 Radiant Pharmacuticals Esomeprazole Magnesium Business Introduction
3.2.1 Radiant Pharmacuticals Esomeprazole Magnesium Shipments, Price, Revenue and Gross profit 2014-2019
3.2.2 Radiant Pharmacuticals Esomeprazole Magnesium Business Distribution by Region
3.2.3 Interview Record
3.2.4 Radiant Pharmacuticals Esomeprazole Magnesium Business Overview
3.2.5 Radiant Pharmacuticals Esomeprazole Magnesium Product Specification
3.3 Teva Pharmaceuticals Esomeprazole Magnesium Business Introduction
3.3.1 Teva Pharmaceuticals Esomeprazole Magnesium Shipments, Price, Revenue and Gross profit 2014-2019
3.3.2 Teva Pharmaceuticals Esomeprazole Magnesium Business Distribution by Region
3.3.3 Interview Record
3.3.4 Teva Pharmaceuticals Esomeprazole Magnesium Business Overview
3.3.5 Teva Pharmaceuticals Esomeprazole Magnesium Product Specification
3.4 Mylan Esomeprazole Magnesium Business Introduction
3.5 Torrent Pharmaceutical Esomeprazole Magnesium Business Introduction
3.6 Camber Pharmaceuticals Esomeprazole Magnesium Business Introduction

About us

BusinessindustryReports.com is digital database of comprehensive market reports for global industries. As a market research company, we take pride in equipping our clients with insights and data that holds the power to truly make a difference to their business. Our mission is singular and well-defined – we want to help our clients envisage their business environment so that they are able to make informed, strategic and therefore successful decisions for themselves.

Media Contact

Business Industry Reports

Pune – India

sales@businessindustryreports.com

+19376349940

This release was published on openPR.